This provider's $5.3M in total Medicare payments ranks in the 99th percentile of Diagnostic Radiology providers nationally.
Medicare payments to this provider grew 51% from 2021 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 73% in 2022
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2021 | $940.05 | $257.98 | 3.64x | $682.07 | $1.3M | 3.6K | 3.4K |
| 2022 | $922.53 | $272.59 | 3.38x | $649.94 | $2.2M | 5.4K | 5.3K |
| 2023 | $828.41 | $290.69 | 2.85x | $537.72 | $1.9M | 4.4K | 4.3K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | 3.0K | $2.3M | $762.85 | 3.41x |
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 436 | $935.5K | $2.1K | 1.63x |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1.5K | $621.7K | $405.83 | 1.70x |
| 78816 | Nuclear medicine study with ct imaging whole body | 185 | $192.5K | $1.0K | 3.51x |
| 78803 | Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, 1 day of imaging | 575 | $157.3K | $273.60 | 2.72x |
| 78306 | Bone and/or joint imaging, whole body | 714 | $145.3K | $203.49 | 2.69x |
| Q9983 | Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries | 60 | $132.9K | $2.2K | 1.26x |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 246 | $101.7K | $413.22 | 1.30x |
| A9562 | Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries | 206 | $85.0K | $412.46 | 1.87x |
| 78814 | Nuclear medicine study limited area with ct scan | 70 | $81.6K | $1.2K | 3.17x |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | 151 | $54.1K | $358.38 | 2.11x |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | 55 | $38.6K | $701.46 | 3.74x |
| 78315 | Bone and/or joint imaging, 3 phase study | 144 | $36.2K | $251.22 | 2.48x |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 351 | $32.0K | $91.13 | 1.92x |
| 78451 | Nuclear medicine study of vessels of heart using drugs or exercise single study | 121 | $31.3K | $258.33 | 1.91x |
| 78708 | Nuclear medicine study of kidney with assessment of blood flow and function, with drugs, single study | 223 | $30.3K | $135.71 | 4.27x |
| A9588 | Fluciclovine f-18, diagnostic, 1 millicurie | 70 | $29.2K | $417.62 | 1.94x |
| 71250 | Diagnostic ct scan of chest | 304 | $27.0K | $88.96 | 7.91x |
| 78264 | Stomach emptying study | 126 | $26.9K | $213.11 | 2.04x |
| 78226 | Imaging of liver and bile duct system | 105 | $24.3K | $231.03 | 2.56x |
This provider submits charges 2.85 times higher than what Medicare actually pays.
A markup ratio of 2.85x means for every $100 Medicare pays, this provider initially charges $285. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data